Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors

Maurizio Alimandi, Ling Mei Wang, Donald Bottaro, Chong Chou Lee, Angera Kuo, Mark Frankel, Paolo Fedi, Careen Tang, Marc E Lippman, Jacalyn H. Pierce

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Interleukin-3 (IL-3)-dependent murine 32D cells do not detectably express epidermal growth factor receptors (EGFRs) and do not proliferate in response to EGF, heregulin (HRG) or other known EGF-like ligands. Here, we report that EGF specifically binds to and can be crosslinked to 32D transfectants co-expressing ErbB2 and ErbB3 (32D.E2/E3), but not to transfectants expressing either ErbB2 or ErbB3 individually. [125I]EGF-crosslinked species detected in 32D.E2/E3 cells were displaced by HRG and betacellulin (BTC) but not by other EGF-like ligands that were analyzed. EGF, BTC and HRG also induced receptor tyrosine phosphorylation, activation of downstream signaling molecules and proliferation of 32D.E2/E3 cells. 32D transfectants were also generated which expressed an ErbB3-EGFR chimera alone (32D.E3-E1) or in combination with ErbB2 (32D.E2/E3-E1). While HRG stimulation of 32D.E3-E1 cells resulted in DNA synthesis and receptor phosphorylation, EGF and BTC were inactive. However, EGF and BTC were as effective as HRG in mediating signaling when ErbB2 was co-expressed with the chimera in the 32D.E2/E3-E1 transfectant. These results provide evidence that ErbB2/ErbB3 binding sites for EGF and BTC are formed by a previously undescribed mechanism that requires co-expression of two distinct receptors. Additional data utilizing MDA MB134 human breast carcinoma cells, which naturally express ErbB2 and ErbB3 in the absence of EGFRs, supported the results obtained employing 32D cells and suggest that EGF and BTC may contribute to the progression of carcinomas that co-express ErbB2 and ErbB3.

Original languageEnglish
Pages (from-to)5608-5617
Number of pages10
JournalEMBO Journal
Volume16
Issue number18
DOIs
StatePublished - Sep 15 1997
Externally publishedYes

Fingerprint

Signal transduction
Epidermal Growth Factor
Signal Transduction
Neuregulin-1
Phosphorylation
Betacellulin
Ligands
Interleukin-3
Chemical activation
Binding Sites
Cells
Breast Neoplasms
Carcinoma

Keywords

  • Betacellulin
  • Epidermal growth factor
  • ErbB2 receptor
  • ErbB3 receptor
  • Signal transduction

ASJC Scopus subject areas

  • Genetics
  • Cell Biology

Cite this

Alimandi, M., Wang, L. M., Bottaro, D., Lee, C. C., Kuo, A., Frankel, M., ... Pierce, J. H. (1997). Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. EMBO Journal, 16(18), 5608-5617. https://doi.org/10.1093/emboj/16.18.5608

Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. / Alimandi, Maurizio; Wang, Ling Mei; Bottaro, Donald; Lee, Chong Chou; Kuo, Angera; Frankel, Mark; Fedi, Paolo; Tang, Careen; Lippman, Marc E; Pierce, Jacalyn H.

In: EMBO Journal, Vol. 16, No. 18, 15.09.1997, p. 5608-5617.

Research output: Contribution to journalArticle

Alimandi, M, Wang, LM, Bottaro, D, Lee, CC, Kuo, A, Frankel, M, Fedi, P, Tang, C, Lippman, ME & Pierce, JH 1997, 'Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors', EMBO Journal, vol. 16, no. 18, pp. 5608-5617. https://doi.org/10.1093/emboj/16.18.5608
Alimandi, Maurizio ; Wang, Ling Mei ; Bottaro, Donald ; Lee, Chong Chou ; Kuo, Angera ; Frankel, Mark ; Fedi, Paolo ; Tang, Careen ; Lippman, Marc E ; Pierce, Jacalyn H. / Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. In: EMBO Journal. 1997 ; Vol. 16, No. 18. pp. 5608-5617.
@article{481710dbd9db423492557e84f3dbf4d1,
title = "Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors",
abstract = "Interleukin-3 (IL-3)-dependent murine 32D cells do not detectably express epidermal growth factor receptors (EGFRs) and do not proliferate in response to EGF, heregulin (HRG) or other known EGF-like ligands. Here, we report that EGF specifically binds to and can be crosslinked to 32D transfectants co-expressing ErbB2 and ErbB3 (32D.E2/E3), but not to transfectants expressing either ErbB2 or ErbB3 individually. [125I]EGF-crosslinked species detected in 32D.E2/E3 cells were displaced by HRG and betacellulin (BTC) but not by other EGF-like ligands that were analyzed. EGF, BTC and HRG also induced receptor tyrosine phosphorylation, activation of downstream signaling molecules and proliferation of 32D.E2/E3 cells. 32D transfectants were also generated which expressed an ErbB3-EGFR chimera alone (32D.E3-E1) or in combination with ErbB2 (32D.E2/E3-E1). While HRG stimulation of 32D.E3-E1 cells resulted in DNA synthesis and receptor phosphorylation, EGF and BTC were inactive. However, EGF and BTC were as effective as HRG in mediating signaling when ErbB2 was co-expressed with the chimera in the 32D.E2/E3-E1 transfectant. These results provide evidence that ErbB2/ErbB3 binding sites for EGF and BTC are formed by a previously undescribed mechanism that requires co-expression of two distinct receptors. Additional data utilizing MDA MB134 human breast carcinoma cells, which naturally express ErbB2 and ErbB3 in the absence of EGFRs, supported the results obtained employing 32D cells and suggest that EGF and BTC may contribute to the progression of carcinomas that co-express ErbB2 and ErbB3.",
keywords = "Betacellulin, Epidermal growth factor, ErbB2 receptor, ErbB3 receptor, Signal transduction",
author = "Maurizio Alimandi and Wang, {Ling Mei} and Donald Bottaro and Lee, {Chong Chou} and Angera Kuo and Mark Frankel and Paolo Fedi and Careen Tang and Lippman, {Marc E} and Pierce, {Jacalyn H.}",
year = "1997",
month = "9",
day = "15",
doi = "10.1093/emboj/16.18.5608",
language = "English",
volume = "16",
pages = "5608--5617",
journal = "EMBO Journal",
issn = "0261-4189",
publisher = "Nature Publishing Group",
number = "18",

}

TY - JOUR

T1 - Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors

AU - Alimandi, Maurizio

AU - Wang, Ling Mei

AU - Bottaro, Donald

AU - Lee, Chong Chou

AU - Kuo, Angera

AU - Frankel, Mark

AU - Fedi, Paolo

AU - Tang, Careen

AU - Lippman, Marc E

AU - Pierce, Jacalyn H.

PY - 1997/9/15

Y1 - 1997/9/15

N2 - Interleukin-3 (IL-3)-dependent murine 32D cells do not detectably express epidermal growth factor receptors (EGFRs) and do not proliferate in response to EGF, heregulin (HRG) or other known EGF-like ligands. Here, we report that EGF specifically binds to and can be crosslinked to 32D transfectants co-expressing ErbB2 and ErbB3 (32D.E2/E3), but not to transfectants expressing either ErbB2 or ErbB3 individually. [125I]EGF-crosslinked species detected in 32D.E2/E3 cells were displaced by HRG and betacellulin (BTC) but not by other EGF-like ligands that were analyzed. EGF, BTC and HRG also induced receptor tyrosine phosphorylation, activation of downstream signaling molecules and proliferation of 32D.E2/E3 cells. 32D transfectants were also generated which expressed an ErbB3-EGFR chimera alone (32D.E3-E1) or in combination with ErbB2 (32D.E2/E3-E1). While HRG stimulation of 32D.E3-E1 cells resulted in DNA synthesis and receptor phosphorylation, EGF and BTC were inactive. However, EGF and BTC were as effective as HRG in mediating signaling when ErbB2 was co-expressed with the chimera in the 32D.E2/E3-E1 transfectant. These results provide evidence that ErbB2/ErbB3 binding sites for EGF and BTC are formed by a previously undescribed mechanism that requires co-expression of two distinct receptors. Additional data utilizing MDA MB134 human breast carcinoma cells, which naturally express ErbB2 and ErbB3 in the absence of EGFRs, supported the results obtained employing 32D cells and suggest that EGF and BTC may contribute to the progression of carcinomas that co-express ErbB2 and ErbB3.

AB - Interleukin-3 (IL-3)-dependent murine 32D cells do not detectably express epidermal growth factor receptors (EGFRs) and do not proliferate in response to EGF, heregulin (HRG) or other known EGF-like ligands. Here, we report that EGF specifically binds to and can be crosslinked to 32D transfectants co-expressing ErbB2 and ErbB3 (32D.E2/E3), but not to transfectants expressing either ErbB2 or ErbB3 individually. [125I]EGF-crosslinked species detected in 32D.E2/E3 cells were displaced by HRG and betacellulin (BTC) but not by other EGF-like ligands that were analyzed. EGF, BTC and HRG also induced receptor tyrosine phosphorylation, activation of downstream signaling molecules and proliferation of 32D.E2/E3 cells. 32D transfectants were also generated which expressed an ErbB3-EGFR chimera alone (32D.E3-E1) or in combination with ErbB2 (32D.E2/E3-E1). While HRG stimulation of 32D.E3-E1 cells resulted in DNA synthesis and receptor phosphorylation, EGF and BTC were inactive. However, EGF and BTC were as effective as HRG in mediating signaling when ErbB2 was co-expressed with the chimera in the 32D.E2/E3-E1 transfectant. These results provide evidence that ErbB2/ErbB3 binding sites for EGF and BTC are formed by a previously undescribed mechanism that requires co-expression of two distinct receptors. Additional data utilizing MDA MB134 human breast carcinoma cells, which naturally express ErbB2 and ErbB3 in the absence of EGFRs, supported the results obtained employing 32D cells and suggest that EGF and BTC may contribute to the progression of carcinomas that co-express ErbB2 and ErbB3.

KW - Betacellulin

KW - Epidermal growth factor

KW - ErbB2 receptor

KW - ErbB3 receptor

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=0030799298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030799298&partnerID=8YFLogxK

U2 - 10.1093/emboj/16.18.5608

DO - 10.1093/emboj/16.18.5608

M3 - Article

C2 - 9312020

AN - SCOPUS:0030799298

VL - 16

SP - 5608

EP - 5617

JO - EMBO Journal

JF - EMBO Journal

SN - 0261-4189

IS - 18

ER -